Jimmy Smith, DO
Critical Care Medicine · Lexington, KYNPI 1598717894
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,288 of the $141,700 with a category attached, or 87.7%. United Therapeutics Corporation accounts for 69.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $62,406 and has fallen 79.2% since, to $12,978 in 2025. Among critical care medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $864.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$99K
- Bayer$42K
- Sandoz$324
- Actelion Pharmaceuticals US, Inc.$127
- Merck$54
- Medtronic$19
- plus $11 from 1 others
Across 14 payments — averaging $2797.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$23K
- Janssen Research & Development, LLC$16K
What the payments were for
- Speaking & faculty fees$124,28888%
- Travel & lodging$13,82410%
- Food & beverage$3,5773%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 115 | $98,916 |
| Bayer | 40 | $42,249 |
| Sandoz | 5 | $324 |
| Actelion Pharmaceuticals US, Inc. | 1 | $127 |
| Merck | 1 | $54 |
| Medtronic | 1 | $19 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,700 in reported general payments places this provider in the 95th percentile of 60 critical care medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 131 | $2,937,533 |
| Tyvaso DpiTreprostinil | 78 | $1,895,200 |
| UptraviSelexipag | 67 | $1,658,055 |
| AdempasRiociguat | 108 | $1,337,850 |
| OpsumitMacitentan | 76 | $954,314 |
| WinrevairSotatercept-Csrk | 52 | $762,313 |
| Ambrisentan | 138 | $416,890 |
| RemodulinTreprostinil Sodium | 22 | $287,180 |
| TreprostinilTreprostinil Sodium | 12 | $180,287 |
| Tadalafil | 70 | $32,154 |
| Sildenafil Citrate | 56 | $19,417 |
| Enoxaparin Sodium | 14 | $5,741 |
| Bumetanide | 27 | $1,066 |
| Potassium Chloride | 47 | $974 |
| Midodrine Hcl | 13 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $127 | $2,612,369143 claims |
| BayerAdempas | $42,249 | $1,337,850108 claims |
| MerckWinrevair | $54 | $762,31352 claims |
| United Therapeutics CorporationRemodulin | $98,916 | $287,18022 claims |
| SandozTreprostinil, Enoxaparin Sodium | $324 | $186,02826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 critical care medicine providers in Kentucky.
Other critical care medicine in Lexington
- Jason BowmanLexington$10K
- Natasha DoughertyLexington$4K
- Kelly BohlLexington$3K
- Michael HollarLexington$2K
- Elijah KakaniLexington$2K
- Susan Hoff-ThomasLexington$996
- Daniel RusuLexington$752
- Hazim BukamurLexington$750
- Laurel FulghamLexington$281
- Wendy BanfiLexington$271
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.